A detailed history of Alps Advisors Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Alps Advisors Inc holds 53,035 shares of AKRO stock, worth $1.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
53,035
Previous 53,939 1.68%
Holding current value
$1.7 Million
Previous $1.27 Million 20.24%
% of portfolio
0.01%
Previous 0.01%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$21.45 - $29.34 $19,390 - $26,523
-904 Reduced 1.68%
53,035 $1.52 Million
Q2 2024

Aug 13, 2024

BUY
$18.31 - $24.62 $260,551 - $350,342
14,230 Added 35.84%
53,939 $1.27 Million
Q1 2024

May 14, 2024

BUY
$17.76 - $31.18 $43,991 - $77,232
2,477 Added 6.65%
39,709 $1 Million
Q4 2023

Feb 14, 2024

SELL
$11.38 - $50.33 $42,970 - $190,046
-3,776 Reduced 9.21%
37,232 $869,000
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $14,128 - $17,921
343 Added 0.84%
41,008 $2.07 Million
Q2 2023

Aug 14, 2023

BUY
$36.89 - $56.88 $363,403 - $560,324
9,851 Added 31.97%
40,665 $1.9 Million
Q1 2023

May 10, 2023

SELL
$37.27 - $50.24 $33,952 - $45,768
-911 Reduced 2.87%
30,814 $1.18 Million
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $373,758 - $612,499
11,177 Added 54.39%
31,725 $1.74 Million
Q3 2022

Nov 14, 2022

SELL
$10.15 - $34.05 $2,324 - $7,797
-229 Reduced 1.1%
20,548 $700,000
Q2 2022

Aug 11, 2022

SELL
$8.0 - $15.01 $121,656 - $228,257
-15,207 Reduced 42.26%
20,777 $196,000
Q1 2022

May 16, 2022

SELL
$12.97 - $22.26 $56,925 - $97,699
-4,389 Reduced 10.87%
35,984 $511,000
Q4 2021

Feb 09, 2022

SELL
$19.87 - $26.24 $46,813 - $61,821
-2,356 Reduced 5.51%
40,373 $854,000
Q3 2021

Nov 15, 2021

SELL
$18.65 - $25.46 $58,616 - $80,020
-3,143 Reduced 6.85%
42,729 $955,000
Q2 2021

Aug 11, 2021

SELL
$24.81 - $32.35 $420,331 - $548,073
-16,942 Reduced 26.97%
45,872 $1.14 Million
Q1 2021

May 07, 2021

BUY
$24.04 - $34.19 $2,211 - $3,145
92 Added 0.15%
62,814 $1.82 Million
Q4 2020

Feb 03, 2021

BUY
$25.12 - $29.89 $464,041 - $552,157
18,473 Added 41.75%
62,722 $1.62 Million
Q3 2020

Nov 04, 2020

BUY
$30.79 - $39.92 $158,137 - $205,029
5,136 Added 13.13%
44,249 $1.36 Million
Q2 2020

Aug 05, 2020

SELL
$19.25 - $26.76 $246,496 - $342,661
-12,805 Reduced 24.66%
39,113 $975,000
Q1 2020

May 06, 2020

SELL
$12.8 - $27.05 $77,529 - $163,841
-6,057 Reduced 10.45%
51,918 $1.1 Million
Q4 2019

Feb 07, 2020

BUY
$17.37 - $27.27 $1.01 Million - $1.58 Million
57,975 New
57,975 $1.29 Million

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.49B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.